Listeria Monocytogenes Infections Treatment Market 2017-Industry Growth Analysis, and Forecast To 2022
The latest market report published by Credence Research,
Inc. “Global Listeria monocytogenes Infections Treatment Market -
Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and
Forecast, 2016 - 2022,” the Listeria monocytogenes infections
treatment market was valued at USD 3,624.9 Mn in 2015, and is expected to reach
USD 5,056.3 Mn by 2022, expanding at a CAGR of 4.74% from 2016 to 2022.
Browse the full report Listeria
monocytogenes Infections Treatment Market - Growth, Share, Opportunities,
Competitive Analysis, and Forecast, 2016 – 2022 at http://www.credenceresearch.com/report/listeria-monocytogenes-infections-treatment-market
Market Insights
Listeria monocytogenes, is an
important pathogen in pregnant patients, neonates, elderly individuals, and
immunocompromised individuals, although an uncommon cause of illness in the
general population. Listeria monocytogenes is a bacterial pathogen capable of
causing severe infections in humans, often with fatal outcomes. According to
USFDA, published studies suggest that 1- 8% of humans may be intestinal
carriers of Listeria. According to Unites States Department of Agriculture
(USDA), Listeria causes about 280 cases of illness in newborns in a typical
year, resulting in 60 deaths and stillbirths. Infants can be infected before
birth, and this infection can cause serious disability in newborns. About 35
infants are disabled as a result of infection from Listeria each year. The key
factors assisting the growth of Listeria monocytogenes infections treatment
market are rise in prevalence of foodborne diseases, stringent laws and
policies issued by FDA, rising demand for healthy and microbial-free food, and
high public awareness related to foodborne diseases in developed countries.
Pipeline Analysis
The phase III drugs included in the
pipeline analysis are Carbavance (The Medicines Company), Telavancin
(Theravance Biopharma Antibiotics, Inc.), Daptomycin (Merck & Co.), Prulifloxacin
(Merck & Co.), and DTaP-IPV/Hib combined vaccine (Sanofi S.A.). According
to market experts, the diversity of the several molecule types in the biologic
group shows a certain level of innovation, with newer avenues being explored in
accounts of recent failures. Overall, late stage clinical trials have
highlighted very few molecules that could potentially replace current
treatments during the forecast period.
Key Market Movements
·
Rising prevalence of foodborne
infections in developed and developing countries
·
The incidence and prevalence of
Listeria monocytogenes infections is high in pediatric and geriatric population
·
Stringent regulatory policies applied
by FDA and other government agencies across the world is expected to reduce the
risk of infection outbreak
·
Novel and developed treatments in
pipeline are expected to assist the overall market growth of Listeria
monocytogenes infections treatment market
·
· Request
Free Sample - http://www.credenceresearch.com/sample-request/57831
About
Us:
Credence
Research is a worldwide market research and counseling firm that serves driving
organizations, governments, non-legislative associations, and not-for-benefits.
We offer our customers some assistance with making enduring enhancements to
their execution and understand their most imperative objectives. Over almost a
century, we’ve manufactured a firm extraordinarily prepared to this task.
Who we
are
Credence
Research is a worldwide firm, containing more than 15 research consultants and
almost 100 research and information professionals.
Our
customers mirror our worldwide nature. Around 45% are in Europe, 30% in the
Americas, 13% in Asia Pacific and 12% in the Middle East and Africa.
Our firm
is intended to work as one. We are a solitary global research organization
united by a solid arrangement of qualities, concentrated on customer effect.
What we do
We serve
customers at each level of their organization, in whatever limit we can be most
helpful, whether as a trusted counsel to top management or as a hands-on mentor
for forefront representatives. For each engagement, we collect a group with the
most suitable experience and ability.
No matter
the challenge, we concentrate on delivering functional and persevering results,
and preparing our customers to develop and lead. We join forces with customers
to place suggestions into practice. Our research specialist work
straightforwardly with customers over long stretches to create workforce
aptitudes, drive operational change, and apply new working strategies.
Contact:
Name: Chris
Smith
Designation: Global
Sales Manager
Ph: +1-800-361-8290
Post a Comment